Remodeling of androgen metabolism network mediated by UGT2B: a new perspective on treatment resistance in prostate cancer
European Journal of Pharmacology · 2026
DOI: 10.1016/j.ejphar.2026.178596 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von YuanYuan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China. Hauptthemen laut MEDLINE: Glucuronosyltransferase, Androgens, Drug Resistance, Neoplasm, Prostatic Neoplasms. Die Arbeit nennt 116 Literaturangaben. Gefördert von: Jiangxi Science and Technology Normal University, Jiangxi Provincial Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Prostate cancer (PCa) is the most common and aggressive malignancy in males worldwide, with its progression influenced by multiple factors. Androgens, the primary regulators of prostate cell growth and physiology, play a pivotal role in PCa pathogenesis through the androgen receptor (AR) signaling pathway, thus earning PCa designations as a hormone-sensitive or hormone-dependent cancer. Current anti-androgen therapies (e.g., androgen deprivation therapy, ADT) have demonstrated initial effectiveness but ultimately failed to prevent progression to castration-resistant prostate cancer (CRPC). Previous research has predominantly focused on AR and its associated signaling pathways. However, UGT2B15 and UGT2B17, as key members of the human UDP-glucuronosyltransferase (UGT) family, serve as critical catalytic enzymes in androgen metabolism. They both efficiently convert androgens into more excretable glucuronidated metabolites, thereby modulating systemic hormone levels, primarily affecting the activation of AR. This article systematically explores the association between the UGT2B subfamily and hormone-dependent prostate cancer, covering various aspects such as gene function, regulatory mechanisms, disease progression, and diagnosis. It elucidates the different roles of UGT2B genes and reveals their significant potential in being developed into biomarkers and therapeutic targets, paving the way for improvements in precision medicine for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China.
- School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China. Electronic address: pengliang@jxstnu.edu.cn.
- School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, 330013, China. Electronic address: 1020221104@jxstnu.edu.cn.
Förderung
- Jiangxi Science and Technology Normal University
- Jiangxi Provincial Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Tu, C., Qin, H., Ma, Y., Yang, Y., Xiong, Y., Peng, L., & Zhang, L. (2026). Remodeling of androgen metabolism network mediated by UGT2B: a new perspective on treatment resistance in prostate cancer. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2026.178596
Vancouver
Wang Y, Tu C, Qin H, Ma Y, Yang Y, Xiong Y, et al. Remodeling of androgen metabolism network mediated by UGT2B: a new perspective on treatment resistance in prostate cancer. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2026.178596
BibTeX
@article{Wang2026,
author = {Wang, YuanYuan and Tu, Chenxi and Qin, Hao and Ma, Yingying and Yang, Yukai and Xiong, Yinhua and Peng, Liang and Zhang, Lin},
title = {Remodeling of androgen metabolism network mediated by UGT2B: a new perspective on treatment resistance in prostate cancer},
journal = {European Journal of Pharmacology},
year = {2026},
doi = {10.1016/j.ejphar.2026.178596}
}
EUVIMED